Symbols / SCPS $0.00 +0.00% Scopus BioPharma Inc.

Healthcare • Biotechnology • United States • PNK
SCPS Chart
About

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 16.83K
Enterprise Value -1.40M Income -8.70M Sales —
Book/sh -0.24 Cash/sh 0.01 Dividend Yield —
Payout 0.00% Employees 13 IPO —
P/E — Forward P/E -0.00 PEG —
P/S — P/B -0.00 P/C —
EV/EBITDA 0.15 EV/Sales — Quick Ratio 0.03
Current Ratio 0.04 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.41 EPS next Y -1.23 EPS Growth —
Revenue Growth — Earnings 2021-11-12 17:00 ROA -5.38%
ROE — ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 42.08M
Shs Float 34.22M Short Float 0.25% Short Ratio 0.22
Short Interest — 52W High 0.01 52W Low 0.00
Beta 35.16 Avg Volume 978.00 Volume 47.08K
Target Price — Recom None Prev Close $0.00
Price $0.00 Change 0.00%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$0.21
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2021-02-16 init Benchmark — → Speculative Buy $20
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
Operating Revenue
0.00
0.00
Operating Expense
11.71
-57.61%
27.63
Research And Development
2.68
-82.15%
15.02
Selling General And Administration
9.03
-28.37%
12.61
General And Administrative Expense
9.03
-28.37%
12.61
Other Gand A
9.03
-28.37%
12.61
Total Expenses
11.71
-57.61%
27.63
Operating Income
-11.71
+57.61%
-27.63
Total Operating Income As Reported
-11.71
+57.61%
-27.63
EBITDA
-11.71
+55.25%
-26.18
Normalized EBITDA
-11.71
+57.61%
-27.63
Reconciled Depreciation
0.00
+15.20%
0.00
EBIT
-11.71
+55.25%
-26.18
Total Unusual Items
—
1.46
Total Unusual Items Excluding Goodwill
—
1.46
Net Income
-11.61
+56.93%
-26.95
Pretax Income
-11.71
+56.54%
-26.95
Net Non Operating Interest Income Expense
0.00
+100.00%
-0.77
Interest Expense Non Operating
0.00
-100.00%
0.77
Net Interest Income
0.00
+100.00%
-0.77
Interest Expense
0.00
-100.00%
0.77
Other Income Expense
—
1.46
Gain On Sale Of Security
—
1.46
Tax Rate For Calcs
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
Net Income Including Noncontrolling Interests
-11.71
+56.54%
-26.95
Net Income From Continuing Operation Net Minority Interest
-11.61
+56.93%
-26.95
Net Income From Continuing And Discontinued Operation
-11.61
+56.93%
-26.95
Net Income Continuous Operations
-11.71
+56.54%
-26.95
Minority Interests
0.11
0.00
Normalized Income
-11.61
+59.13%
-28.41
Net Income Common Stockholders
-11.61
+56.93%
-26.95
Diluted EPS
-0.55
+64.74%
-1.56
Basic EPS
-0.55
+64.74%
-1.56
Basic Average Shares
21.09
+22.27%
17.25
Diluted Average Shares
21.09
+22.27%
17.25
Diluted NI Availto Com Stockholders
-11.61
+56.93%
-26.95
Line Item Trend 2022-12-31 2021-12-31
Total Assets
0.39
-95.21%
8.19
Current Assets
0.39
-95.24%
8.18
Cash Cash Equivalents And Short Term Investments
0.12
-98.43%
7.94
Cash And Cash Equivalents
0.12
-98.43%
7.94
Cash Financial
0.12
-98.43%
7.94
Prepaid Assets
—
0.24
Other Current Assets
0.27
+9.72%
0.24
Total Non Current Assets
0.00
-20.25%
0.00
Net PPE
0.00
-20.25%
0.00
Total Liabilities Net Minority Interest
7.45
+78.75%
4.17
Current Liabilities
7.45
+78.75%
4.17
Payables And Accrued Expenses
7.20
+72.70%
4.17
Payables
0.18
+51.25%
0.12
Other Payable
0.18
+51.25%
0.12
Current Accrued Expenses
7.03
+73.31%
4.05
Other Current Liabilities
0.25
—
Total Non Current Liabilities Net Minority Interest
0.00
0.00
Stockholders Equity
-6.56
-263.40%
4.02
Common Stock Equity
-6.56
-263.40%
4.02
Capital Stock
0.02
+0.00%
0.02
Common Stock
0.02
+0.00%
0.02
Preferred Stock
0.00
0.00
Share Issued
21.09
+0.00%
21.09
Ordinary Shares Number
21.09
+0.00%
21.09
Additional Paid In Capital
46.52
+2.15%
45.54
Retained Earnings
-53.06
-28.01%
-41.46
Gains Losses Not Affecting Retained Earnings
-0.00
+94.28%
-0.09
Minority Interest
-0.50
0.00
Other Equity Adjustments
-0.00
+94.28%
-0.09
Total Equity Gross Minority Interest
-7.06
-275.79%
4.02
Total Capitalization
-6.56
-263.40%
4.02
Working Capital
-7.06
-275.97%
4.01
Invested Capital
-6.56
-263.40%
4.02
Net Tangible Assets
-6.56
-263.40%
4.02
Tangible Book Value
-6.56
-263.40%
4.02
Interest Payable
—
0.00
Other Equity Interest
-0.03
—
Line Item Trend 2022-12-31 2021-12-31
Operating Cash Flow
-8.13
+28.87%
-11.42
Cash Flow From Continuing Operating Activities
-8.13
+28.87%
-11.42
Net Income From Continuing Operations
-11.71
+56.54%
-26.95
Depreciation Amortization Depletion
0.00
+15.20%
0.00
Depreciation
0.00
+15.20%
0.00
Depreciation And Amortization
0.00
+15.20%
0.00
Other Non Cash Items
—
13.47
Stock Based Compensation
0.35
-47.47%
0.67
Operating Gains Losses
—
-1.46
Gain Loss On Investment Securities
—
-1.46
Change In Working Capital
3.23
+13.85%
2.84
Change In Prepaid Assets
-0.02
+76.55%
-0.10
Change In Payables And Accrued Expense
3.01
+2.18%
2.94
Change In Other Current Liabilities
0.25
0.00
Investing Cash Flow
-0.00
+22.36%
-0.00
Cash Flow From Continuing Investing Activities
-0.00
+22.36%
-0.00
Net PPE Purchase And Sale
-0.00
+22.36%
-0.00
Purchase Of PPE
-0.00
+22.36%
-0.00
Capital Expenditure
-0.00
+22.36%
-0.00
Financing Cash Flow
0.24
-98.62%
17.56
Cash Flow From Continuing Financing Activities
0.24
-98.62%
17.56
Net Issuance Payments Of Debt
0.00
+100.00%
-0.10
Issuance Of Debt
—
0.00
Repayment Of Debt
0.00
+100.00%
-0.10
Long Term Debt Issuance
—
0.00
Long Term Debt Payments
—
-0.10
Net Long Term Debt Issuance
—
-0.10
Short Term Debt Payments
0.00
+100.00%
-0.10
Net Short Term Debt Issuance
0.00
+100.00%
-0.10
Net Common Stock Issuance
0.00
-100.00%
20.10
Net Other Financing Charges
0.24
+109.92%
-2.44
Changes In Cash
-7.89
-228.65%
6.13
Effect Of Exchange Rate Changes
0.07
+452.22%
-0.02
Beginning Cash Position
7.94
+333.54%
1.83
End Cash Position
0.12
-98.43%
7.94
Free Cash Flow
-8.13
+28.87%
-11.43
Interest Paid Supplemental Data
0.00
-100.00%
0.03
Income Tax Paid Supplemental Data
—
0.00
Common Stock Issuance
0.00
-100.00%
20.10
Issuance Of Capital Stock
0.00
-100.00%
20.10
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category